Median OS came in at nearly 17 months for the Elahere group, compared to just over 13 months for chemo, while median progression-free survival (PFS) was 5.6 and 4 months, respectively. The study ...

We came across a bullish thesis on AbbVie Inc. (ABBV) on Substack by Magnus Ofstad. In this article, we will summarize the ...

The treatment demonstrated a significant and clinically meaningful 35% reduction in the risk of disease progression or death, compared to standard chemotherapy. Patients treated with Elahere had a ...

The study showed a 33% reduction in the risk of death compared to chemotherapy, whilst improving progression-free survival by 35%. Rivals to Elahere are headed by Eisai's farletuzumab ecteribulin ...

[Looking] back to 2024 [conference data], we noted a handful of patients who had received Elahere and had had target lesion reductions ... per meter squared compared to investigator's choice ...

Despite Imbruvica's 7% decline, the oncology portfolio grew 11% through Venclexta and Elahere's strong performance. The neuroscience segment grew 16.6%, while aesthetics remained stable despite ...